Mergers & Acquisitions

Yaral Pharma will begin commercializing the first product from IBSA’s corporate pipeline of authorized generics in January 2023.

Trü Frü, a whole-fruit snacking brand, will operate as business unit within Mars.

Sezaby is the first and only product approved for treating seizures in neonatal patients.

Tzield is the first and only treatment indicated to delay the onset of stage 3 type 1 diabetes in adult and pediatric patients aged 8 years old and older with stage 2 type 1 diabetes.

For the third quarter, Rite Aid reported a net loss of $67.1 million, or $1.23 loss per share, adjusted net loss of $7.9 million, or 14 cents loss per share.

Levothyroxine sodium is an important medicine used in hospitals for the treatment of myxedema coma.

Fueled by record growth, RevSpring makes its home in a city surrounded by healthcare leaders.

The store is anticipated to open in the second quarter of 2024.